Trump Says Iran Ceasefire Near Collapse as Oil Prices Surge 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
US Stock Futures Hold Steady Ahead of CPI Data and Iran Conflict Concerns 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
Why the future of marijuana legalization remains hazy despite high public support 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
